Search details
1.
An anti-CD3/anti-CLL-1 bispecific antibody for the treatment of acute myeloid leukemia.
Blood
; 129(5): 609-618, 2017 02 02.
Article
in English
| MEDLINE | ID: mdl-27908880
2.
Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study.
Lancet Oncol
; 16(6): 704-15, 2015 Jun.
Article
in English
| MEDLINE | ID: mdl-25925619
3.
Antibody-drug conjugates for the treatment of B-cell non-Hodgkin's lymphoma and leukemia.
Future Oncol
; 9(3): 355-68, 2013 Mar.
Article
in English
| MEDLINE | ID: mdl-23469971
4.
Exogenous insulin-like growth factor 1 enhances thymopoiesis predominantly through thymic epithelial cell expansion.
Blood
; 112(7): 2836-46, 2008 Oct 01.
Article
in English
| MEDLINE | ID: mdl-18658030
5.
CCL25 increases thymopoiesis after androgen withdrawal.
Blood
; 112(8): 3255-63, 2008 Oct 15.
Article
in English
| MEDLINE | ID: mdl-18694999
6.
Mitigating the risk of cytokine release syndrome in a Phase I trial of CD20/CD3 bispecific antibody mosunetuzumab in NHL: impact of translational system modeling.
NPJ Syst Biol Appl
; 6(1): 28, 2020 08 28.
Article
in English
| MEDLINE | ID: mdl-32859946
7.
Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS).
Lancet Haematol
; 6(5): e254-e265, 2019 May.
Article
in English
| MEDLINE | ID: mdl-30935953
8.
Murine models of chronic graft-versus-host disease: insights and unresolved issues.
Biol Blood Marrow Transplant
; 14(4): 365-78, 2008 Apr.
Article
in English
| MEDLINE | ID: mdl-18342778
9.
Assessment of Correlation Between Early and Late Efficacy Endpoints to Identify Potential Surrogacy Relationships in Non-Hodgkin Lymphoma: a Literature-Based Meta-analysis of 108 Phase II and Phase III Studies.
AAPS J
; 19(3): 669-681, 2017 05.
Article
in English
| MEDLINE | ID: mdl-28224402
10.
Phase I Study of the Anti-CD22 Antibody-Drug Conjugate Pinatuzumab Vedotin with/without Rituximab in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma.
Clin Cancer Res
; 23(5): 1167-1176, 2017 Mar 01.
Article
in English
| MEDLINE | ID: mdl-27601593
11.
Anti-CD20/CD3 T cell-dependent bispecific antibody for the treatment of B cell malignancies.
Sci Transl Med
; 7(287): 287ra70, 2015 May 13.
Article
in English
| MEDLINE | ID: mdl-25972002
12.
Phase II randomized study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer.
J Clin Oncol
; 31(9): 1157-63, 2013 Mar 20.
Article
in English
| MEDLINE | ID: mdl-23382472
13.
Effects of Trastuzumab Emtansine (T-DM1) on QT Interval and Safety of Pertuzumab Plus T-DM1 in Patients With Previously Treated Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer.
Clin Pharmacol Drug Dev
; 2(1): 11-24, 2013 Jan.
Article
in English
| MEDLINE | ID: mdl-27121556
14.
DCDT2980S, an anti-CD22-monomethyl auristatin E antibody-drug conjugate, is a potential treatment for non-Hodgkin lymphoma.
Mol Cancer Ther
; 12(7): 1255-65, 2013 Jul.
Article
in English
| MEDLINE | ID: mdl-23598530
15.
Clinical implications of pathophysiological and demographic covariates on the population pharmacokinetics of trastuzumab emtansine, a HER2-targeted antibody-drug conjugate, in patients with HER2-positive metastatic breast cancer.
J Clin Pharmacol
; 52(5): 691-703, 2012 May.
Article
in English
| MEDLINE | ID: mdl-21953571
16.
A population pharmacokinetic/pharmacodynamic model of thrombocytopenia characterizing the effect of trastuzumab emtansine (T-DM1) on platelet counts in patients with HER2-positive metastatic breast cancer.
Cancer Chemother Pharmacol
; 70(4): 591-601, 2012 Oct.
Article
in English
| MEDLINE | ID: mdl-22886072
17.
Drug interaction potential of trastuzumab emtansine (T-DM1) combined with pertuzumab in patients with HER2-positive metastatic breast cancer.
Curr Drug Metab
; 13(7): 911-22, 2012 Sep 01.
Article
in English
| MEDLINE | ID: mdl-22475266
18.
Catabolic fate and pharmacokinetic characterization of trastuzumab emtansine (T-DM1): an emphasis on preclinical and clinical catabolism.
Curr Drug Metab
; 13(7): 901-10, 2012 Sep 01.
Article
in English
| MEDLINE | ID: mdl-22475269
19.
Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody-drug conjugate in development for the treatment of HER2-positive cancer.
Cancer Chemother Pharmacol
; 69(5): 1229-40, 2012 May.
Article
in English
| MEDLINE | ID: mdl-22271209
20.
Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy.
J Clin Oncol
; 29(4): 398-405, 2011 Feb 01.
Article
in English
| MEDLINE | ID: mdl-21172893